Systemic-onset juvenile idiopathic arthritis

Autoimmunity Reviews

Volumn 15, Issue 9, 2016, Pages 931-934

  Cimaz, Rolando ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Autoinflammatory; Juvenile idiopathic arthritis; Systemic

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 6; IMMUNOSUPPRESSIVE AGENT;

ARTHRITIS; CLINICAL FEATURE; FEVER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LABORATORY TEST; LYMPHADENOPATHY; MACROPHAGE ACTIVATION SYNDROME; PATHOGENESIS; PROGNOSIS; RASH; REVIEW; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; ANIMAL; ARTHRITIS, JUVENILE; AUTOIMMUNITY; COMPLICATION; IMMUNOLOGY;

ANIMALS; ARTHRITIS, JUVENILE; AUTOIMMUNITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MACROPHAGE ACTIVATION SYNDROME;

EID: 85002786979     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2016.07.004     Document Type: Review

References (33)

1. [1] Hersh, A.O., Prahalad, S., Immunogenetics of juvenile idiopathic arthritis: a comprehensive review. J Autoimmun 64 (2015), 113–124.
2. [2] Petty, R.E., Southwood, T.R., Manners, P., Baum, J., Glass, D.N., Goldenberg, J., et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31 (2004), 390–392.
3. [3] Rochette, E., Duché, P., Merlin, E., Juvenile idiopathic arthritis and physical activity: possible inflammatory and immune modulation and tracks for interventions in young populations. Autoimmun Rev 14 (2015), 726–734.
4. [4] Eisenstein, E.M., Berkun, Y., Diagnosis and classification of juvenile idiopathic arthritis. J Autoimmun 48–49 (2014), 31–33.
5. [5] Thierry, S., Fautrel, B., Lemelle, I., Guillemin, F., Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine 81 (2014), 112–117.
6. [6] Pascual, V., Allantaz, F., Arce, E., Punaro, M., Banchereau, J., Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201 (2005), 1479–1486.
7. [7] Allantaz, F., Chaussabel, D., Stichweh, D., Bennett, L., Allman, W., Mejias, A., et al. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med 204 (2007), 2131–2144.
8. [8] Wakil, S.M., Monies, D.M., Abouelhoda, M., Al-Tassan, N., Al-Dusery, H., Naim, E.A., et al. Association of a mutation in LACC1 with a monogenic form of systemic juvenile idiopathic arthritis. Arthritis Rheumatol 67 (2015), 288–295.
9. [9] Ombrello, M.J., Remmers, E.F., Tachmazidou, I., Grom, A., Foell, D., Haas, J.P., et al. HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proc Natl Acad Sci U S A 112 (2015), 15970–15975.
10. [10] Kimura, Y., Weiss, J.E., Haroldson, K.L., Lee, T., Punaro, M., Oliveira, S., et al. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 65 (2013), 745–752.
11. [11] Belot, A., Bader-Meunier, B., Niaudet, P., Salomon, R., Prieur, A.M., Noel, L.H., et al. ANCA-associated glomerulonephritis in systemic-onset juvenile idiopathic arthritis. Am J Kidney Dis 59 (2012), 439–443.
12. [12] Frosch, M., Ahlmann, M., Vogl, T., Wittkowski, H., Wulffraat, N., Foell, D., et al. The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1 beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 60 (2009), 883–891.
13. [13] Minoia, F., Davi, S., Horne, A., Demirkaya, E., Bovis, F., Li, C., et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol 66 (2014), 3160–3169.
14. [14] Davi, S., Minoia, F., Pistorio, A., Horne, A., Consolaro, A., Rosina, S., et al. Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Arthritis Rheumatol 66 (2014), 2871–2880.
15. [15] Cifaldi, L., Prencipe, G., Caiello, I., Bracaglia, C., Locatelli, F., De Benedetti, F., et al. Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. Arthritis Rheumatol 67 (2015), 3037–3046.
16. [16] de Jager, W., Vastert, S.J., Beekman, J.M., Wulffraat, N.M., Kuis, W., Coffer, P.J., et al. Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 60 (2009), 2782–2793.
17. [17] Beukelman, T., Patkar, N.M., Saag, K.G., Tolleson-Rinehart, S., Cron, R.Q., DeWitt, E.M., et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 63 (2011), 465–482.
18. [18] DeWitt, E.M., Kimura, Y., Beukelman, T., Nigrovic, P.A., Onel, K., Prahalad, S., et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 64 (2012), 1001–1010.
19. [19] Otten, M.H., Prince, F.H., Armbrust, W., et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA 306 (2011), 2340–2347.
20. [20] Lequerré, T., Quartier, P., Rosellini, D., Alaoui, F., De Bandt, M., Mejjad, O., et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 67 (2008), 302–308.
21. [21] Gattorno, M., Piccini, A., Lasiglie, D., Tassi, S., Brisca, G., Carta, S., et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic onset juvenile idiopathic arthritis. Arthritis Rheum 58 (2008), 1505–1515.
22. [22] De Benedetti, F., Martini, A., Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease?. J Rheumatol 25 (1998), 203–207.
23. [23] Ringold, S., Weiss, P.F., Beukelman, T., DeWitt, E.M., Illowite, N.T., Kimura, Y., et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum 65 (2013), 2499–2512.
24. [24] Quartier, P., Allantaz, F., Cimaz, R., Pillet, P., Messiaen, C., Bardin, C., et al. A multicenter, randomized, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 70 (2011), 747–754.
25. [25] Nigrovic, P.A., Mannion, M., Prince, F.H., Zeft, A., Rabinovich, C.E., van Possum, M.A., et al. Anakinra as first-line disease modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 63 (2011), 545–555.
26. [26] Vastert, S.J., de Jager, W., Noordman, B.J., Holzinger, D., Kuis, W., Prakken, B.J., et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol 66 (2014), 1034–1043.
27. [27] Ruperto, N., Brunner, H.I., Quartier, P., Constantin, T., Wulffraat, N., Hoffer, G., et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 367 (2012), 2396–2406.
28. [28] Yokota, S., Imagawa, T., Mori, M., Miyamae, T., Amhara, Y., Takei, S., et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371 (2008), 998–1006.
29. [29] De Benedetti, F., Brunner, H.I., Ruperto, N., Kenwright, A., Wright, S., Calvo, I., et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 367 (2012), 2385–2395.
30. [30] Ilowite, N.T., Prather, K., Lokhnygina, Y., Schanberg, L.E., Elder, M., Milojevic, D., et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol 66 (2014), 2570–2579.
31. [31] Miettunen, P.M., Narendran, A., Jayanthan, A., Behrens, E.M., Cron, R.Q., Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford) 50 (2011), 417–419.
32. [32] Grom, A.A., Ilowite, N.T., Pascual, V., Brunner, H.I., Martini, A., Lovell, D., et al. Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with canakinumab. Arthritis Rheumatol 68 (2016), 218–228.
33. [33] Eng, S.W., Duong, T.T., Rosenberg, A.M., Morris, Q., Yeung, R.S., REACCH OUT and BBOP Research Consortia, The biologic basis of clinical heterogeneity in juvenile idiopathic arthritis. Arthritis Rheumatol. 66:12 (2014), 3463–3475, 10.1002/art.38875.